Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia Formula (I).

Abstract: Disclosed is a sensor, comprising: a housing; a detecting element provided inside the housing; a first cylinder provided inside the housing and sleeved outside the detecting element, the first cylinder having an amount of elastic deformation in a direction intersecting a surface around the detecting element; a particle filler, for filling an inner cavity of the housing. When external environment produces mechanical shock to the sensor or the sensor produces mechanical vibration, the limiting action of the first cylinder and the particle filler enables the detecting element to only have very little vibration displacement or even no vibration displacement with respect to the housing. The external mechanical shock can be partially or completely absorbed by the first cylinder and the particle filler, so as to reduce vibration displacement of the detecting element caused by the shock.

Abstract: A track pin may comprise a body that includes a generally cylindrical configuration defining an axis of rotation, a circumferential direction and a radial direction, the body defining a first end, a second end and a peripheral surface extending from the first end to the second end. The peripheral surface may include a first lobed portion spaced axially away from the first end and the second end and including a series of convex arcuate segments and concave arcuate segments joined to each other tangentially, forming an undulating surface.

Abstract: A wall-hung bracket for a projection screen is provided, including a guide rail, a slider and a lead screw. The guide rail is configured for being fixed on a wall along a vertical direction. The slider is slidingly connected to the guide rail. The slider is configured for being connected to a rear surface of a projection screen. The lead screw is provided with threads, and the lead screw is in threaded connection to the slider. When the lead screw rotates on its longitudinal axis, the slider slides in the vertical direction along the guide rail driven by the lead screw.

Abstract: A wall-hung bracket for a projection screen is provided, including a guide rail, a slider and a lead screw. The guide rail is configured for being fixed on a wall along a vertical direction. The slider is slidingly connected to the guide rail. The slider is configured for being connected to a rear surface of a projection screen. The lead screw is provided with threads, and the lead screw is in threaded connection to the slider. When the lead screw rotates on its longitudinal axis, the slider slides in the vertical direction along the guide rail driven by the lead screw.

Abstract: A track pin may comprise a body that includes a generally cylindrical configuration defining an axis of rotation, a circumferential direction and a radial direction, the body defining a first end, a second end and a peripheral surface extending from the first end to the second end. The peripheral surface may include a first lobed portion spaced axially away from the first end and the second end and including a series of convex arcuate segments and concave arcuate segments joined to each other tangentially, forming an undulating surface.

Abstract: The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract: A system for providing casting design advisement for designing a cast component is provided. The system includes an integrated design environment, the integrated design environment receiving a concept design for the cast component, the concept design being user-modifiable. The system also includes a plurality of design advisory modules, the plurality of design advisory modules determining physics models associated with the concept design for the cast component and providing advisement analysis for the concept design based on the physics models. The system includes a design rule logic solver for receiving concept design features associated with the concept design and comparing the concept design features with stored casting design rules to determine a geometry modification guide.

Abstract: Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.

Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.

Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.

Abstract: Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119.

Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.

Abstract: Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119.